Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Short position
Neuren Pharmaceuticals (ASX:NEU) has 2.95% of its shares on issue reported as short positions as of 5 Oct 2026, or about 3,735,393 shares. Over the past 30 days that figure has fallen 0.08 percentage points, and over 90 days it has fallen 1.96 percentage points. Its highest recorded short interest was 6.51% in June 2026. NEU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4NEU community
Research Threads
Bull, bear, catalyst, and news-reaction posts tied directly to NEU.
Start the first NEU research thread
Anchor the conversation with a thesis, a catalyst, or a question worth debating.